Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| XAI.X | 0.006212 | 0.000033 | +0.54% |
| Xai cryptocurrency | |||
| XTJA | 34.79 | N/A | N/A |
| Innovator U.S. Equity Accelerated Plus ETF - January (XTJA) | |||
| RLC.X | 0.411509 | -0.000069 | -0.02% |
| iExec RLC cryptocurrency | |||
| REI.X | 0.001590 | -0.000008 | -0.52% |
| REI Network cryptocurrency | |||
| BETH.X | 2047.152600 | -84.104004 | -3.95% |
| Beacon ETH cryptocurrency | |||
A.I.dvisor indicates that over the last year, HALO has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To HALO | 1D Price Change % | ||
|---|---|---|---|---|
| HALO | 100% | +0.06% | ||
| AXON - HALO | 47% Loosely correlated | -0.21% | ||
| ONC - HALO | 40% Loosely correlated | +1.60% | ||
| VRTX - HALO | 37% Loosely correlated | -0.54% | ||
| INCY - HALO | 36% Loosely correlated | -1.30% | ||
| VCYT - HALO | 34% Loosely correlated | -7.18% | ||
More | ||||
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HALO declined for three days, in 163 of 272 cases, the price declined further within the following month. The odds of a continued downward trend are 60%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HALO as a result. In 46 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
The Moving Average Convergence Divergence Histogram (MACD) for HALO turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 20 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
HALO moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in 276 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
HALO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 257 of 328 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HALO's P/B Ratio (81.939) is slightly higher than the industry average of (3.498). P/E Ratio (29.192) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.968) is also within normal values, averaging (440.869).